argenx SE American Depositary Shares (ARGX)
Stock · NASDAQ · Health Care
$819.19as of 10/16/2026
Price chart
Active signals
ARGX Signal Track Record
How signals performed across all stocks →What ARGX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +2.5% | 59% | October 8, 2026 |
| Bollinger Band Breakout | 28 | +0.6% | 54% | August 17, 2026 |
| Bollinger Band Breakdown | 17 | +5.1% | 65% | October 2, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +4.9% | 67% | August 3, 2026 |
| Any 20-session window (baseline) | +1.6% | 58% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for t…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 1,863
- Website
- www.argenx.com/
Fundamentals
- 1-day range
- $813.05$843.61
- Market cap
- $54.32B
- P/E (trailing)
- 21.26
- P/E (forward)
- 23.02
- EPS (trailing)
- $37.84
- Dividend yield
- —
- Beta
- 1.54
- Avg. volume
- 328.2K
Forecasts
23 analyst ratings
argenx SE American Depositary Shares Competitors
Chosen by industry and closest market cap.
- ARGXargenx SE American Depositary Shares$819.14▼ 3.21%Market cap $54.32BP/E 21.26$568.4$925
- RVMDRevolution Medicines Inc. Common Stock$177.96▼ 5.97%Market cap $42.05BP/E —$47.45$224.31
- BIIBBiogen Inc. Common Stock$232.65▼ 1.15%Market cap $30.48BP/E 42.27$138$238.24
- BNTXBioNTech SE American Depositary Share$87.71▼ 2.76%Market cap $22.91BP/E —$79.52$124
- MRNAModerna Inc. Common Stock$218.01▼ 7.82%Market cap $21.50BP/E —$22.28$227.46
- NBIXNeurocrine Biosciences Inc. Common Stock$135.71▼ 0.91%Market cap $16.25BP/E 19.57$122.14$186.12
- EXELExelixis Inc. Common Stock$62.23▼ 0.95%Market cap $13.12BP/E 17.49$33.76$61.66
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ARGX argenx SE American Depositary Shares | $54.32B | 21.26 | $819.14 | ▼ 3.21% | $568.4$925 |
| RVMD Revolution Medicines Inc. Common Stock | $42.05B | — | $177.96 | ▼ 5.97% | $47.45$224.31 |
| BIIB Biogen Inc. Common Stock | $30.48B | 42.27 | $232.65 | ▼ 1.15% | $138$238.24 |
| BNTX BioNTech SE American Depositary Share | $22.91B | — | $87.71 | ▼ 2.76% | $79.52$124 |
| MRNA Moderna Inc. Common Stock | $21.50B | — | $218.01 | ▼ 7.82% | $22.28$227.46 |
| NBIX Neurocrine Biosciences Inc. Common Stock | $16.25B | 19.57 | $135.71 | ▼ 0.91% | $122.14$186.12 |
| EXEL Exelixis Inc. Common Stock | $13.12B | 17.49 | $62.23 | ▼ 0.95% | $33.76$61.66 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- argenx (ENXTBR:ARGX) Stock May Be Fully Priced After Its 185% RunYahoo · 10/10/2026
- argenx Meets Primary Endpoint in Phase II Celiac Disease StudyYahoo · 10/9/2026
- European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for WeekYahoo · 10/9/2026
- Evercore ISI Group Maintains Outperform on argenx, Lowers Price Target to $1078Benzinga · 10/9/2026
- ARGX Stock Down on Stopping Late-Stage Autoimmune Disease StudyYahoo · 10/9/2026
- argenx (ENXTBR:ARGX) Gets Mixed Trial News, Is It Still Overvalued?Yahoo · 10/9/2026
- argenx: The Sjögren's Selloff Looks OverdoneSeekingAlpha · 10/9/2026
- Baird Maintains Neutral on argenx, Lowers Price Target to $823Benzinga · 10/9/2026
- Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targetsbenzinga · 10/6/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 29.26M
- Total value held
- $18.60B
- Institutional holders
- 474
- Unknown4.99M
- Unknown3.37M
- Unknown2.54M
- Unknown2.26M
- Unknown1.47M
- Unknown1.02M
- Unknown1.00M
- Unknown808.3K
- Unknown709.4K
- Unknown594.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Argenx featured in analyst lists ahead of Q3 report
Argenx has been featured in recent analyst lists from Zacks and Guggenheim. The company's ongoing deal impact on Halozyme Therapeutics remains a point of interest. Looking ahead, argenx is scheduled to report its third-quarter 2026 financial results on October 22, 2026. European ADRs traded with mixed results during the week.
Argenx featured in analyst lists ahead of Q3 report. Argenx has been featured in recent analyst lists from Zacks and Guggenheim. The company's ongoing deal impact on Halozyme Therapeutics remains a point of interest. Looking ahead, argenx is scheduled to report its third-quarter 2026 financial results on October 22, 2026. European ADRs traded with mixed results during the week.